With Al­im­ta patent cliff loom­ing, Lil­ly plots stronger foothold in front­line NSCLC with Cyra­mza

With Lil­ly’s foothold in the non-small cell lung can­cer (NSCLC) field weak­en­ing as its Al­im­ta fran­chise march­es to­ward a patent cliff, an­oth­er can­cer treat­ment man­u­fac­tured by the drug­mak­er could be used as a front­line treat­ment in the lu­cra­tive mar­ket. On Tues­day, the In­di­anapo­lis com­pa­ny said its drug, Cyra­mza, in com­bi­na­tion with Roche’s Tarce­va, helped stem the spread and growth of can­cer as an ini­tial treat­ment in cer­tain pa­tients with metasta­t­ic NSCLC in a piv­otal study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.